{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:35:36Z","timestamp":1787618136422,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Changchun GeneScience Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03611-6","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:25:04Z","timestamp":1779182704000},"page":"3432-3450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial"],"prefix":"10.1007","volume":"43","author":[{"given":"Zaihua","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9762-2663","authenticated-orcid":false,"given":"Hejian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"1","key":"3611_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","volume":"5","author":"N Dalbeth","year":"2019","unstructured":"Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69.","journal-title":"Nat Rev Dis Primers"},{"issue":"23","key":"3611_CR2","doi-asserted-by":"publisher","first-page":"e2308749","DOI":"10.1002\/smll.202308749","volume":"20","author":"C Chen","year":"2024","unstructured":"Chen C, Wang J, Guo Y, Li M, Yang K, Liu Y, et al. Monosodium urate crystal-induced pyroptotic cell death in neutrophil and macrophage facilitates the pathological progress of gout. Small. 2024;20(23):e2308749.","journal-title":"Small"},{"issue":"48","key":"3611_CR3","doi-asserted-by":"publisher","first-page":"e46231","DOI":"10.1097\/MD.0000000000046231","volume":"104","author":"K Shi","year":"2025","unstructured":"Shi K, Guo Y, You T. Global burden of gout in age groups 10 to 54 years from 1990 to 2021: trend of the global burden of disease study. Medicine (Baltimore). 2025;104(48):e46231.","journal-title":"Medicine (Baltimore)"},{"key":"3611_CR4","doi-asserted-by":"publisher","first-page":"762820","DOI":"10.1155\/2015\/762820","volume":"2015","author":"R Liu","year":"2015","unstructured":"Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis. Biomed Res Int. 2015;2015:762820.","journal-title":"Biomed Res Int"},{"key":"3611_CR5","doi-asserted-by":"publisher","first-page":"1577265","DOI":"10.3389\/fpubh.2025.1577265","volume":"13","author":"J Wang","year":"2025","unstructured":"Wang J, Zhao Y, Zhao B, Zhang Y. Global burden and future projections of geriatric gout (1990\u20132021): a comprehensive analysis and Bayesian Age-Period-Cohort modeling. Front Public Health. 2025;13:1577265.","journal-title":"Front Public Health"},{"key":"3611_CR6","doi-asserted-by":"publisher","first-page":"1008598","DOI":"10.3389\/fpubh.2022.1008598","volume":"10","author":"B Zhu","year":"2022","unstructured":"Zhu B, Wang Y, Zhou W, Jin S, Shen Z, Zhang H, et al. Trend dynamics of gout prevalence among the Chinese population, 1990\u20132019: a joinpoint and age-period-cohort analysis. Front Public Health. 2022;10:1008598.","journal-title":"Front Public Health"},{"key":"3611_CR7","doi-asserted-by":"publisher","first-page":"j1794","DOI":"10.1136\/bmj.j1794","volume":"357","author":"SK Rai","year":"2017","unstructured":"Rai SK, Fung TT, Lu N, Keller SF, Curhan GC, Choi HK. The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study. BMJ. 2017;357:j1794.","journal-title":"BMJ"},{"issue":"10","key":"3611_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","volume":"17","author":"LK Stamp","year":"2021","unstructured":"Stamp LK, Farquhar H, Pisaniello HL, Vargas-Santos AB, Fisher M, Mount DB, et al. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. Nat Rev Rheumatol. 2021;17(10):633\u201341.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"3611_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.33549\/physiolres.935631","volume":"74","author":"S Chen","year":"2025","unstructured":"Chen S, Li Z, Deng X, Gao L. Advances in understanding the mechanisms of treatment for gouty arthritis: a comprehensive review. Physiol Res. 2025;74(5):693\u2013710.","journal-title":"Physiol Res"},{"issue":"7081","key":"3611_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237\u201341.","journal-title":"Nature"},{"issue":"3","key":"3611_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4078\/jrd.2022.29.3.140","volume":"29","author":"SK Kim","year":"2022","unstructured":"Kim SK. The mechanism of the NLRP3 inflammasome activation and pathogenic implication in the pathogenesis of gout. J Rheum Dis. 2022;29(3):140\u201353.","journal-title":"J Rheum Dis"},{"issue":"6","key":"3611_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3611_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"3611_CR14","doi-asserted-by":"crossref","unstructured":"Butler F, Alghubayshi A, Roman Y. The epidemiology and genetics of hyperuricemia and gout across major racial groups: a literature review and population genetics secondary database analysis. J Pers Med. 2021;11(3):231.","DOI":"10.3390\/jpm11030231"},{"key":"3611_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12881-015-0208-8","volume":"16","author":"ZW Zhou","year":"2015","unstructured":"Zhou ZW, Cui LL, Han L, Wang C, Song ZJ, Shen JW, et al. Polymorphisms in GCKR, SLC17A1 and SLC22A12 were associated with phenotype gout in Han Chinese males: a case-control study. BMC Med Genet. 2015;16:66.","journal-title":"BMC Med Genet"},{"key":"3611_CR16","doi-asserted-by":"publisher","first-page":"204201882412272","DOI":"10.1177\/20420188241227295","volume":"15","author":"T Han","year":"2024","unstructured":"Han T, Chen W, Qiu X, Wang W. Epidemiology of gout\u2014global burden of disease research from 1990 to 2019 and future trend predictions. Ther Adv Endocrinol Metab. 2024;15:20420188241227296.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"3611_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12967-025-06072-7","volume":"23","author":"Y Xue","year":"2025","unstructured":"Xue Y, Chu T, Hu J, Gou W, Zhang N, Li J, et al. Firsekibart in acute gouty arthritis. J Transl Med. 2025;23(1):91.","journal-title":"J Transl Med"},{"issue":"9","key":"3611_CR18","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1007\/s12325-025-03279-4","volume":"42","author":"H Liu","year":"2025","unstructured":"Liu H, Yuan Y, Tian W, Luo T, Xu Q, Zhu X, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of Firsekibart, an anti-interleukin-1beta monoclonal antibody, in healthy Chinese participants: a randomized, double-blind, placebo-controlled phase 1 study. Adv Ther. 2025;42(9):4611\u201325.","journal-title":"Adv Ther"},{"key":"3611_CR19","doi-asserted-by":"publisher","unstructured":"Li C, Zhang J, Yu H, Lu M, Yang S, Liu C, et al. Efficacy and safety of firsekibart in treatment of active systemic juvenile idiopathic arthritis: a randomized phase 2 study. Rheumatol Ther. 2026. https:\/\/doi.org\/10.1007\/s40744-026-00830-9","DOI":"10.1007\/s40744-026-00830-9"},{"issue":"11","key":"3611_CR20","doi-asserted-by":"publisher","first-page":"e70111","DOI":"10.1002\/acr2.70111","volume":"7","author":"Y Yu","year":"2025","unstructured":"Yu Y, Xue Y, Hu J, Zhang N, Li R, Guo H, et al. Firsekibart as a prophylactic treatment for acute gout flare in participants initiating urate-lowering therapy: a phase 2, randomized, open-label, multicenter, active-controlled trial. ACR Open Rheumatol. 2025;7(11):e70111.","journal-title":"ACR Open Rheumatol"},{"issue":"5","key":"3611_CR21","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40744-025-00790-6","volume":"12","author":"N Kong","year":"2025","unstructured":"Kong N, Xue Y, Mao L, Qian L, Guo H, Hu J, et al. Efficacy and safety of firsekibart compared to etoricoxib for gout flares: a phase 2, multicenter, open-label, active-controlled, randomized non-inferiority trial. Rheumatol Ther. 2025;12(5):975\u201390.","journal-title":"Rheumatol Ther"},{"issue":"8","key":"3611_CR22","first-page":"101015","volume":"6","author":"Y Xue","year":"2025","unstructured":"Xue Y, Chu T, Hu J, Gou W, Zhang N, Li J, et al. Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: a randomized phase 3 trial. Innovation (Camb). 2025;6(8):101015.","journal-title":"Innovation (Camb)"},{"issue":"11","key":"3611_CR23","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839\u201348.","journal-title":"Ann Rheum Dis"},{"key":"3611_CR24","doi-asserted-by":"publisher","unstructured":"Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen T, Janssen M, Kok MR, et al. Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford). 2019; 58(8):1344\u201352. https:\/\/doi.org\/10.1093\/rheumatology\/key402","DOI":"10.1093\/rheumatology\/key402"},{"issue":"8","key":"3611_CR25","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3899\/jrheum.131226","volume":"41","author":"JS Sundy","year":"2014","unstructured":"Sundy JS, Schumacher HR, Kivitz A, Weinstein SP, Wu R, King-Davis S, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol. 2014;41(8):1703\u201311.","journal-title":"J Rheumatol"},{"issue":"11","key":"3611_CR26","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/rheumatology\/ket265","volume":"52","author":"P Chandratre","year":"2013","unstructured":"Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford). 2013;52(11):2031\u201340.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"3611_CR27","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/ijcp.12521","volume":"68","author":"JD Hirsch","year":"2014","unstructured":"Hirsch JD, Gnanasakthy A, Lale R, Choi K, Sarkin AJ. Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures. Int J Clin Pract. 2014;68(12):1503\u20137.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"3611_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-023-03098-4","volume":"25","author":"N Schlesinger","year":"2023","unstructured":"Schlesinger N, Pillinger MH, Simon LS, Lipsky PE. Interleukin-1beta inhibitors for the management of acute gout flares: a systematic literature review. Arthritis Res Ther. 2023;25(1):128.","journal-title":"Arthritis Res Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03611-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03611-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03611-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:04:52Z","timestamp":1785517492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03611-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3611"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03611-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Qian Xu, Fei Gu, Yuling Lian, and Xu Zhang are employees of Changchun GeneScience Pharmaceutical Co., Ltd. Zaihua Zhu, Yu Xue, Tianshu Chu, Jiankang Hu, Wei Gou, Ning Zhang, Juan Li, Jing Yu, Rongping Li, Rongbin Li, Long Qian, Xinwang Duan, Lihua Duan, and Hejian Zou declare that they have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study followed Good Clinical Practice guidelines, and the principles of the Declaration of Helsinki. Ethical approval was obtained from the ethics review committee of Huashan hospital, Fudan University (2022, clinical review No. 976) and the ethical committees at each study site. Each patient provided informed consent before joining the study. The trial was registered at ClinicalTrials.gov (\n                      NCT05983445\n                      ).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}